INVO Fertility, Inc. (IVF) — Institutional Holders, Q2 2026
10 institutional investment managers reported a IVF position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $248.7K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
IVF in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- Virtu FinancialNew · +63,174 sh+$120.0K
- Scientech ResearchNew · +32,338 sh+$61.4K
- StoneX GroupNew · +15,702 sh+$29.8K
- SUSQUEHANNA INTERNATIONAL GROUP, LLPNew · +11,463 sh+$21.8K
- Tower Research Capital (TRC)New · +8,155 sh+$15.5K
Biggest sellers
- MarinerSold out · -100,000 sh-$190.0K
- ARMISTICE CAPITALSold out · -71,866 sh-$136.5K
- GEODE CAPITAL MANAGEMENTSold out · -16,848 sh-$32.0K
- UBS Group AGSold out · -3,321 sh-$6.3K
- CITIGROUPSold out · -15 sh-$28.00
IVF 13F holders ranked 1–10 of 10
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | Virtu Financial#1 · 63,174 sh | 63,174 | $120.0K | <0.01% | New |
| 2 | Scientech Research#2 · 32,338 sh | 32,338 | $61.4K | 0.05% | New |
| 3 | StoneX Group#3 · 15,702 sh | 15,702 | $29.8K | <0.01% | New |
| 4 | SUSQUEHANNA INTERNATIONAL GROUP, LLP#4 · 11,463 sh | 11,463 | $21.8K | 0.00% | New |
| 5 | Tower Research Capital (TRC)#5 · 8,155 sh | 8,155 | $15.5K | <0.01% | New |
| 6 | SBI Securities , Ltd.#6 · 53 sh | 53 | $101.00 | — | +1666.7% |
| 7 | Caitong International Asset Management , Ltd#7 · 38 sh | 38 | $72.00 | 0.00% | New |
| 8 | Integrated Wealth Concepts#8 · 8 sh | 8 | $15.00 | 0.00% | New |
| 9 | DANSKE BANK A/S#9 · 1 sh | 1 | $2.00 | 0.00% | New |
| 10 | HUNTINGTON NATIONAL BANK#10 · 1 sh | 1 | $0.00 | 0.00% | 0.0% |
Funds that sold out of IVF in Q2 2026 (5)
Held IVF at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| Mariner100,000 sh | 100,000 | $272.0K |
| ARMISTICE CAPITAL71,866 sh | 71,866 | $195.5K |
| GEODE CAPITAL MANAGEMENT16,848 sh | 16,848 | $45.8K |
| UBS Group AG3,321 sh | 3,321 | $9.0K |
| CITIGROUP15 sh | 15 | $41.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.